Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia
a Federal University of
Minas Gerais, Belo Horizonte, Brazil: Unit of Paediatric
Endocrinology, b Department of
Paediatrics, c Department of Medicine, Federal
University of São Paulo, Brazil
Correspondence to: Dr I N Silva, Department of Paediatrics, Faculty of Medicine, Federal University of Minas Gerais, Avenue Alfredo Balena 190, 30130-100 Belo Horizonte, MG, Brazil.
Accepted 5 June 1997
The influence of 15 or 25 mg/m2 of daily oral
hydrocortisone with fludrocortisone 0.1 mg/day on growth and laboratory
findings was evaluated in a prospective randomised crossover trial over 12 months in 26 children with 21-hydroxylase deficiency. Nine non-salt
losers had fludrocortisone stopped for a further six month period.
Height velocity was significantly decreased during treatment with 25 mg/m2 as compared with 15 mg/m2. This was the
most sensitive indicator of corticosteroid treatment excess. A dose
dependent effect upon plasma concentrations of 17-hydroxyprogesterone,
testosterone, and androstenedione was found but increased values
were still detected in more than half of the determinations made during
the 25 mg/m2 period. Height velocity and
17-hydroxyprogesterone concentrations were positively correlated.
Growth hormone response to clonidine stimulation and insulin-like
growth factor-1 concentrations were both within reference values and
there was no difference between treatment periods. Withdrawal of
fludrocortisone did not result in any difference for the non-salt
losers. It was concluded that 25 mg/m2 of hydrocortisone
depressed growth in children with congenital adrenal hyperplasia, and
that full suppression, or even normalisation, of plasma concentrations
of 17-hydroxyprogesterone and androgens should not be considered a
treatment goal, but instead an indication of corticosteroid treatment excess.
© 1997 by Archives of Disease in Childhood
This article has been cited by other articles:
-
Chakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maitre, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., Carel, J.-C., Leger, J., Kuttenn, F., Polak, M., Touraine, P.
(2008). Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.. Eur J Endocrinol
158: 879-887
[Abstract] [Full Text] -
Shulman, D. I., Francis, G. L., Palmert, M. R., Eugster, E. A., for the Lawson Wilkins Pediatric Endocrine Society,
(2008). Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development. Pediatrics
121: e975-e983
[Abstract] [Full Text] -
Stikkelbroeck, N. M. M. L., van't Hof-Grootenboer, B. A. E., Hermus, A. R. M. M., Otten, B. J., van't Hof, M. A.
(2003). Growth Inhibition by Glucocorticoid Treatment in Salt Wasting 21-Hydroxylase Deficiency: In Early Infancy and (Pre)Puberty. J. Clin. Endocrinol. Metab.
88: 3525-3530
[Abstract] [Full Text] -
Collett-Solberg, P. F.
(2001). Congenital Adrenal Hyperplasia: From Genetics and Biochemistry to Clinical Practice, Part 2. CLIN PEDIATR
40: 125-132
[Abstract] -
White, P. C., Speiser, P. W.
(2000). Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Endocr. Rev.
21: 245-291
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



